Haley Laken

Tabby Therapeutics is a privately held company developing a first in class engineered B cell therapy • Drove the design and execution of critical scientific experiments to inform board decisions • Accountable for efficient company operations globally • Secured funding through an insider seed extension

• Comprehensively assessed strategic alternatives that would maximize the value to shareholders, ultimately leading to a cash offer and CVR covering active programs • Oversight of program leadership and management, clinical pharmacology, and bioanalytical methods

• Continuously assessed portfolio outcomes and financial conditions to adapt and optimize corporate strategy • Collaborated with internal stakeholders to craft and disseminate external communications including: quarterly earnings releases, earnings Q&A, SEC filings, R&D day presentation, and partnership pitches • Spearheaded technical diligence efforts for inbound and outbound opportunities, providing critical insights to inform decision-making and negotiations

• Built and executed development strategies that aligned with organizational goals, leveraging data and market insights to inform program positioning and success criteria • Fostered a culture of high-performing teams through effective leadership, coaching and mentorship resulting in increased cross functional collaboration and employee engagement • Established and chaired the development governance committee as a collaborative forum for robust discussion on program data and strategy • Delivered comprehensive updates on portfolio and corporate strategy to the Board of Directors on a quarterly basis, driving collaboration and progress toward business goals

Initiated and developed a biologics immunotherapy portfolio of 4 programs as the chair of the Joint Steering Committee of a strategic external collaboration with a $16M budget driving innovation and portfolio expansion in the organization Led cross-functional program teams to key achievements creating portfolio value • Successful IND and clinical study start for three independent programs within a 17-month period • Initiated the registration program for Jemperli leading to BLA submission in just over 4 years from IND Organized company-wide events that promoted teamwork and cohesive company culture

Drove the rapid development of 2 peptide therapeutics through clinical POC in metabolic disease and gastrointestinal disorders through a successful outsourcing model Established the early development strategy for IMCIVREE™ (setmelanotide) CRO and CMO selection, contracting, and execution for exploratory and GLP preclinical studies, clinical studies and GMP manufacturing Directed up to 10 consultants spanning all development functions Advancement of relamorelin into phase 2 leading to asset acquisition

Development Director for programs in metabolic disease, hematology and oncology

Preclinical team leader for biotherapeutics in all therapeutic areas responsible for recommending timely advancement through drug development milestones

Biotherapeutic process development scientific leader